GoodRx Holdings, Inc. (NASDAQ:GDRX – Get Rating) – Stock analysts at SVB Leerink issued their Q1 2023 earnings per share estimates for GoodRx in a report issued on Monday, August 1st. SVB Leerink analyst S. Davis expects that the company will post earnings of $0.06 per share for the quarter. SVB Leerink has a “Market Perform” rating and a $10.00 price objective on the stock. The consensus estimate for GoodRx’s current full-year earnings is $0.02 per share. SVB Leerink also issued estimates for GoodRx’s Q2 2023 earnings at $0.05 EPS, Q3 2023 earnings at $0.06 EPS and Q4 2023 earnings at $0.09 EPS.
Several other brokerages have also issued reports on GDRX. The Goldman Sachs Group lowered shares of GoodRx from a “buy” rating to a “neutral” rating and lowered their price target for the company from $12.00 to $9.00 in a research note on Thursday, June 9th. Bank of America assumed coverage on GoodRx in a report on Monday, June 6th. They set a “buy” rating and a $11.00 target price on the stock. Cowen lowered their target price on shares of GoodRx from $22.00 to $9.00 and set a “market perform” rating on the stock in a report on Monday, June 13th. Credit Suisse Group cut their price target on shares of GoodRx from $22.00 to $10.00 in a research note on Wednesday, May 11th. Finally, Royal Bank of Canada restated a “sector perform” rating and set a $6.50 price objective (down from $8.00) on shares of GoodRx in a research note on Thursday, June 23rd. One investment analyst has rated the stock with a sell rating, eleven have issued a hold rating and six have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Hold” and a consensus price target of $16.39.
GoodRx Stock Performance
GoodRx (NASDAQ:GDRX – Get Rating) last posted its quarterly earnings data on Monday, May 9th. The company reported $0.03 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.02 by $0.01. The business had revenue of $203.30 million during the quarter, compared to the consensus estimate of $200.61 million. GoodRx had a positive return on equity of 2.86% and a negative net margin of 1.86%. GoodRx’s quarterly revenue was up 26.7% on a year-over-year basis. During the same period last year, the company earned ($0.01) earnings per share.
Hedge Funds Weigh In On GoodRx
A number of institutional investors have recently modified their holdings of the business. CIBC Asset Management Inc boosted its stake in GoodRx by 2.4% in the fourth quarter. CIBC Asset Management Inc now owns 16,124 shares of the company’s stock valued at $527,000 after buying an additional 376 shares in the last quarter. Rockefeller Capital Management L.P. boosted its stake in shares of GoodRx by 5.2% in the 4th quarter. Rockefeller Capital Management L.P. now owns 8,563 shares of the company’s stock valued at $279,000 after purchasing an additional 421 shares in the last quarter. Capital Investment Advisory Services LLC grew its holdings in shares of GoodRx by 5.7% during the 4th quarter. Capital Investment Advisory Services LLC now owns 10,255 shares of the company’s stock valued at $335,000 after purchasing an additional 550 shares during the last quarter. CWM LLC increased its position in GoodRx by 50.2% during the 1st quarter. CWM LLC now owns 2,224 shares of the company’s stock worth $43,000 after purchasing an additional 743 shares in the last quarter. Finally, AdvisorNet Financial Inc lifted its stake in GoodRx by 275.0% in the 1st quarter. AdvisorNet Financial Inc now owns 1,875 shares of the company’s stock valued at $36,000 after purchasing an additional 1,375 shares during the last quarter. Institutional investors and hedge funds own 52.60% of the company’s stock.
GoodRx Holdings, Inc, through its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices through GoodRx codes that are used to save money on prescriptions across the United States.
- Get a free copy of the StockNews.com research report on GoodRx (GDRX)
- Can FuelCell Energy Surge Higher This Year?
- Is It Time to Take a Ride on Cedar Fair Stock?
- Time To Take A Serious Look At Nikola Stock As Production Starts
- These Are The Top Insider Buying Stocks For July
- Chipotle Mexican Grill Or Shake Shak? Which Is The Tastier Play
Want More Great Investing Ideas?
- Bear Market Game Plan!
- The 10 Best Stocks to Own in 2022
- 7 Stocks to Buy and Hold Forever
- 3 Stocks to DOUBLE This Year
Receive News & Ratings for GoodRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GoodRx and related companies with MarketBeat.com's FREE daily email newsletter.